Merck Serono and Illumina Enter Strategic Collaboration for Diagnostics in Oncology
Advertisement
Merck Serono and Illumina, Inc., announced a collaboration to expand the development of a universal next-generation sequencing-based oncology diagnostic for clinical trials of targeted cancer therapies.
Under the terms of the agreement, Merck Serono and Illlumina will work together to develop assays that detect and simultaneously measure multiple genetic variants in a single tumor sample in a clinical trial setting. Illumina’s successful regulatory track record was an important consideration in the collaboration, as next-generation sequencing platforms cleared by a regulatory agency could accelerate the development of an assay and facilitate the registration of a companion diagnostic.
“Our collaboration with Illumina around next-generation sequencing will enable us to perform genome studies at a pace unheard of a few years ago, and could lead to the development of several diagnostics,” said Susan Herbert, Head of Global Business Development at Merck Serono. “This collaboration will strengthen the position of Merck Serono as a global leader in precision medicine in oncology.”
The collaboration will include development of the diagnostic, worldwide regulatory approvals, and global commercialization.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
Loss of the Y chromosome discovered as a new risk factor for heart disease - Men who lose their Y chromosome in part of their blood cells have an increased risk of cardiovascular disease
Bruker announces acquisition of a spin-off from Ghent University - Acquisition expands nuclear molecular imaging portfolio
Researchers discover way to inhibit major cancer gene
Swiss biotechnology startup HAYA Therapeutics announces collaboration with Lilly - Discovery of novel regulatory genomic targets for obesity and related metabolic conditions using proprietary RNA platform
Medigenomix Acquires an Exclusive License for another Genetic Polymorphisms in G-Proteins for Applications in Pharmacogenetics
Breakthrough: Prospect of blood test for Parkinson’s disease for the first time - A new method reliably detects protein changes in blood that are typical of Parkinson's disease: "The results are really sensational"
Evotec and Bayer partner to develop new treatments to fight kidney diseases
Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent
Vaccine-induced CD4 T cells have adverse effect in a mouse model of infection - Research offers a 'cautionary tale' for the development of CD4 T cell vaccines
Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b
Merck Plans to Invest € 1 Billion at the Darmstadt Site - Employment guarantee extended until the end of 2025
